Press Releases

Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.

The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.

A Kids’ Brain Tumor Cure Foundation, Solving Kids’ Cancer, and the Ty Louis Campbell (TLC) Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.

The National Institute for Health and Care Excellence (NICE) heard an appeal led by Solving Kids’ Cancer (SKC) against its recent decision to deny children in the UK treatment that is proven to significantly increase the chance of survival for children diagnosed with an aggressive childhood cancer, neuroblastoma.

Solving Kids’ Cancer, in conjunction with Kids v Cancer and the broader childhood cancer community, applauds the introduction of the RACE for Children Act by Senator Michael Bennet, Senator Marco Rubio, Representative Michael McCaul, Representative G.K. Butterfield, Representative Chris Van Hollen, and Representative Sean Duffy.

The Solving Kids Cancer 6th Annual Spring Celebration was held June 8 at 583 Park Avenue, raising $650,000 for childhood cancer research. This year’s Spring Celebration honored Roger Jeffs, PhD, president and Co-CEO of United Therapeutics, and Yoganathan Ratheesan, Founder and Chairman of Lebara Group.

September is National Childhood Cancer Awareness Month, and the concept is simple: to join Solving Kids’ Cancer in honoring those children who are undergoing treatment, celebrating those who have won the battle, and remembering those who we have lost by sharing social media posts with the hashtag #CCAM throughout the month.  The anonymous donor has agreed to donate $1 for every share up to $10,000.

Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors. Solving Kids’ Cancer and The Catherine Elizabeth Blair Memorial Foundation awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer.

One hundred percent of all donations collected by these two moms will help fund a clinical trial for kids with relapsed neuroblastoma, a deadly childhood cancer. Children with relapsed or refractory neuroblastoma have few or little curative options today.